Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study

CR. Bolen, M. Klanova, M. Trneny, LH. Sehn, J. He, J. Tong, JN. Paulson, E. Kim, U. Vitolo, A. Di Rocco, G. Fingerle-Rowson, T. Nielsen, G. Lenz, MZ. Oestergaard

. 2020 ; 105 (9) : 2298-2307. [pub] 20200901

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020182

Diffuse large B-cell lymphoma represents a biologically and clinically heterogeneous diagnostic category with well-defined cell-of-origin subtypes. Using data from the GOYA study (NCT01287741), we characterized the mutational profile of diffuse large B-cell lymphoma and evaluated the prognostic impact of somatic mutations in relation to cell-of-origin. Targeted DNA next-generation sequencing was performed in 499 formalin-fixed paraffin-embedded tissue biopsies from previously untreated patients. Prevalence of genetic alterations/mutations was examined. Multivariate Cox regression was used to evaluate the prognostic effect of individual genomic alterations. Of 465 genes analyzed, 59 were identified with mutations occurring in at least 10 of 499 patients (≥2% prevalence); 334 additional genes had mutations occurring in ≥1 patient. Single nucleotide variants were the most common mutation type. On multivariate analysis, BCL2 alterations were most strongly associated with shorter progression-free survival (multivariate hazard ratio: 2.6; 95% confidence interval: 1.6 to 4.2). BCL2 alterations were detected in 102 of 499 patients; 92 had BCL2 translocations, 90% of whom had germinal center B-cell-like diffuse large B-cell lymphoma. BCL2 alterations were also significantly correlated with BCL2 gene and protein expression levels. Validation of published mutational subsets revealed consistent patterns of co-occurrence, but no consistent prognostic differences between subsets. Our data confirm the molecular heterogeneity of diffuse large B-cell lymphoma, with potential treatment targets occurring in distinct cell-of-origin subtypes. clinicaltrials.gov identifier: NCT01287741.

000      
00000naa a2200000 a 4500
001      
bmc21020182
003      
CZ-PrNML
005      
20210830101816.0
007      
ta
008      
210728s2020 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2019.227892 $2 doi
035    __
$a (PubMed)33054054
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Bolen, Christopher R $u Bioinformatics and Computational Biology, Genentech Inc., South San Francisco, CA, USA
245    10
$a Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study / $c CR. Bolen, M. Klanova, M. Trneny, LH. Sehn, J. He, J. Tong, JN. Paulson, E. Kim, U. Vitolo, A. Di Rocco, G. Fingerle-Rowson, T. Nielsen, G. Lenz, MZ. Oestergaard
520    9_
$a Diffuse large B-cell lymphoma represents a biologically and clinically heterogeneous diagnostic category with well-defined cell-of-origin subtypes. Using data from the GOYA study (NCT01287741), we characterized the mutational profile of diffuse large B-cell lymphoma and evaluated the prognostic impact of somatic mutations in relation to cell-of-origin. Targeted DNA next-generation sequencing was performed in 499 formalin-fixed paraffin-embedded tissue biopsies from previously untreated patients. Prevalence of genetic alterations/mutations was examined. Multivariate Cox regression was used to evaluate the prognostic effect of individual genomic alterations. Of 465 genes analyzed, 59 were identified with mutations occurring in at least 10 of 499 patients (≥2% prevalence); 334 additional genes had mutations occurring in ≥1 patient. Single nucleotide variants were the most common mutation type. On multivariate analysis, BCL2 alterations were most strongly associated with shorter progression-free survival (multivariate hazard ratio: 2.6; 95% confidence interval: 1.6 to 4.2). BCL2 alterations were detected in 102 of 499 patients; 92 had BCL2 translocations, 90% of whom had germinal center B-cell-like diffuse large B-cell lymphoma. BCL2 alterations were also significantly correlated with BCL2 gene and protein expression levels. Validation of published mutational subsets revealed consistent patterns of co-occurrence, but no consistent prognostic differences between subsets. Our data confirm the molecular heterogeneity of diffuse large B-cell lymphoma, with potential treatment targets occurring in distinct cell-of-origin subtypes. clinicaltrials.gov identifier: NCT01287741.
650    _2
$a protokoly antitumorózní kombinované chemoterapie $7 D000971
650    _2
$a cyklofosfamid $x terapeutické užití $7 D003520
650    _2
$a doxorubicin $x terapeutické užití $7 D004317
650    _2
$a lidé $7 D006801
650    12
$a difúzní velkobuněčný B-lymfom $x diagnóza $x farmakoterapie $x genetika $7 D016403
650    _2
$a mutace $7 D009154
650    _2
$a prednison $x terapeutické užití $7 D011241
650    _2
$a prognóza $7 D011379
650    _2
$a protoonkogenní proteiny c-bcl-2 $x genetika $7 D019253
650    12
$a protoonkogenní proteiny c-myc $x genetika $7 D016271
650    _2
$a rituximab $x terapeutické užití $7 D000069283
650    _2
$a vinkristin $x terapeutické užití $7 D014750
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Klanova, Magdalena $u Bioinformatics and Computational Biology, Genentech Inc., South San Francisco, CA, USA
700    1_
$a Trneny, Marek $u 1st Department of Medicine, Charles University General Hospital, Prague, Czech Republic
700    1_
$a Sehn, Laurie H $u British Columbia Cancer Centre for Lymphoid Cancer, Vancouver, Canada
700    1_
$a He, Jie $u Foundation Medicine, Inc., Cambridge, MA, USA
700    1_
$a Tong, Jing $u Foundation Medicine, Inc., Cambridge, MA, USA
700    1_
$a Paulson, Joseph N $u Department of Biostatistics, Product Development, Genentech Inc., South San Francisco, CA, USA
700    1_
$a Kim, Eugene $u Department of Biostatistics, Product Development, Genentech Inc., South San Francisco, CA, USA
700    1_
$a Vitolo, Umberto $u A.O. Universitaria Città della Salute e della Scienza di Torino, Ematologia, Torino, Italy
700    1_
$a Di Rocco, Alice $u Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
700    1_
$a Fingerle-Rowson, Günter $u Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland
700    1_
$a Nielsen, Tina $u Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland
700    1_
$a Lenz, Georg $u Department of Medicine A,Hematology, Oncology and Pneumology, University Hospital Muenster,Muenster
700    1_
$a Oestergaard, Mikkel Z $u Oncology Biomarker Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 105, č. 9 (2020), s. 2298-2307
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33054054 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101816 $b ABA008
999    __
$a ok $b bmc $g 1690885 $s 1140628
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 105 $c 9 $d 2298-2307 $e 20200901 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace